论文信息 - [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.

[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.

The pharmacological characteristics of [3H]dofetilide binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing human ether-á-go-go related gene (HERG) K+ channels. The classIII antiarrhythmic compounds dofetilide, clofilium, 4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidyl]carbonyl]methanesulfonanilide (E-4031), N-methyl-N-[2-[methyl-(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzene-sulfonamide (WAY-123,398) and d-sotalol all inhibited [3H]dofetilide binding. In addition, the structurally unrelated compounds pimozide, terfenadine and haloperidol, all of which prolong the QT interval in man, also inhibited binding. These data indicate that a [3H]dofetilide binding assay using HERG membranes may help identify compounds that prolong the QT interval.

[1] O. Pongs,et al. Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[2] A. J. Pennington,et al. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? , 2001, European journal of pharmacology.

[3] T J Campbell,et al. HERG K+ channels: friend and foe. , 2001, Trends in pharmacological sciences.

[4] S. Heinemann,et al. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241 , 1997, FEBS letters.

[5] H. J. Olverman,et al. Characterisation of [125 I]-apamin binding sites in rat brain membranes and HEK293 cells transfected with SK channel subtypes , 2001, Neuropharmacology.

[6] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[7] D. Rampe,et al. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. , 2000, European journal of pharmacology.

[8] F. Ponti,et al. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.